Areas of Focus
- Tumor Pharmacology
Work Experience
- 2017-11~Present - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Associate Researcher
- 2017-04~2017-10 - Chinese Academy of Sciences Shanghai Institute of Materia Medica - Assistant Researcher
- 2013-07~2017-03 - East China Normal University - Assistant Researcher
- 2011-10~2013-06 - University of Michigan - Postdoctoral Researcher
- 2006-09~2011-06 - Zhejiang University - PhD Student
- 2002-09~2006-06 - Zhejiang University - Bachelor's Degree
Academic Background & Achievements
- 2006-09--2011-06 PhD: Zhejiang University
- 2002-09--2006-06 Bachelor's Degree: Zhejiang University
Publications
- Dysregulation of iron homeostasis by TfR-1 renders EZH2 wild type diffuse large B-cell lymphoma resistance to EZH2 inhibition, 9th author, 2023
- PI3K inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma, 3rd author, 2021
- Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor-SN38 Conjugates for Targeted Drug Accumulation, 5th author, 2020
- AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition, 3rd author, 2019
- NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3, 6th author, 2019
- Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression, 5th author, 2019
- ES2 enhances the efficacy of chemotherapeutic agents in ABCB1-overexpressing cancer cells in vitro and in vivo, 1st author, 2018
- Characterization of a near-infrared fluorescent DCPO-tagged glucose analogue for cancer cell imaging, 1st author, 2017
- Structure-based design and synthesis of imidazo1,2-apyridine derivatives as novel and potent Nek2 inhibitors with invitro and invivo antitumor activities, 2nd author, 2017
- Pyrrolidine Dithiocarbamate (PDTC) Attenuates Cancer Cachexia by Affecting Muscle Atrophy and Fat Lipolysis, 6th author, 2017
- Preclinical activity of MBM-5 in gastrointestinal cancer by inhibiting NEK2 kinase activity, 1st author, 2016
- Targeting NEK2 as a promising therapeutic approach for cancer treatment, 1st author, 2016
- Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases, 7th author, 2016
- NIR fluorescent DCPO glucose analogues and their application in cancer cell imaging, 2nd author, 2016
Awards
- Patent (2018): A new branched linker for targeted drug delivery systems, 4th author, Patent No: ZL201510005869.X
- Patent (2017): A glucose-conjugated near-infrared dye and its preparation method and application, 3rd author, Patent No: ZL201610111482.7
